|
Market Closed -
Euronext Bruxelles
23:55:00 30/09/2026 HKT
|
5-day change | 1st Jan Change | ||
| 205.10 EUR | -0.82% |
|
-3.07% | -14.04% |
| 09-30 | Merck's experimental skin disease drug succeeds in mid-stage study | RE |
| 09-29 | UCB Presents Data From Innovative Myasthenia Gravis Portfolio At AANEM Annual Meeting And MGFA Scientific Session | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 44.68B | |||||
| 1,056B | |||||
| 645B | - | ||||
| 465B | |||||
| 368B | |||||
| 335B |
- Stock Market
- Stocks
- UCB Stock
- Charts UCB
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
